News – Page 3 – www.brainwork.md

17th June 2020

Malaria drug brings new hope for glioblastoma patients

https://www.brainwork.md/content/uploads/2020/06/brainwork_malaria_glioblastoma.jpg 4794 3196 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 17th June 2020 22nd June 2020

Glioblastoma is a very aggressive form of cancer. Even though there is a low number of patients who live longer than 5 years after diagnosis – a statistic that researchers…

Anna Stelling, PhD
0
0

29th May 2020

Does COVID-19 affect the brain?

https://www.brainwork.md/content/uploads/2020/05/MPR761-KSA-Brainwork-2020-EAN-GC-V00-03-20200529_main-image-e1590771856294.jpg 1920 1080 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 29th May 2020 2nd June 2020

With EAN going virtual this year, the global SARS-CoV2 pandemic was never far from the attendees’ minds. After a brief overview of the putative mechanisms for SARS-CoV2 accessing the brain,…

Anne Carter, MA (Cantab)
0
0

29th May 2020

Optimising early diagnosis of Alzheimer’s disease – mission impossible?

https://www.brainwork.md/content/uploads/2020/05/MPR761-KSA-Brainwork-2020-EAN-EM-V00-02-20200529_article-1-e1590764532778.jpg 1920 1080 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 29th May 2020 2nd June 2020

Alzheimer’s disease (AD) is a very common malady of the elderly, currently affecting 5.8 million Americans above the age of 65. It accounts for 60–80% of all dementia cases, which…

Anna Stelling, PhD
0
0

29th May 2020

Siponimod shows promising long-term efficacy in SPMS patients

https://www.brainwork.md/content/uploads/2020/05/Brainwork-LongTermEfficacy-e1590771801837.jpg 1920 1280 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 29th May 2020 2nd June 2020

While researchers are looking at the potential of stem cells in the treatment of multiple sclerosis (MS), novel, promising immune-modulating therapies are being developed. At this year’s virtual EAN Congress,…

Anna Stelling, PhD
0
0

29th May 2020

Paediatric multiple sclerosis: Adding to our knowledge

https://www.brainwork.md/content/uploads/2020/05/MPR761-KSA-Brainwork-2020-EAN-GC-V00-03-20200528_probability-marbles-e1590771823562.jpg 1920 1080 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 29th May 2020 29th May 2020

Data suggest that between 2 and 5% of patients with multiple sclerosis (MS) are under 18 years old,1 yet there is only one approved treatment option in this population.2,3 During…

Anne Carter, MA (Cantab)
0
0

Elderly man on bench by himself outdoors

29th May 2020

Why do some glioblastoma patients live longer than others?

https://www.brainwork.md/content/uploads/2020/05/Brainwork-glioblastoma-e1590771764413.jpg 1920 1280 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 29th May 2020 29th May 2020

Why do some glioblastoma patients live longer than others? Alice Laurenge (Institut du Cerveau et de la Moelle épinière, Sorbonne Université and Hôspitaux universitaire La Pitié Salpêtrière – Charles Foix,…

Anna Stelling, PhD
1
0

29th May 2020

How to choose antiepileptic drug treatment for refractory epilepsy?

https://www.brainwork.md/content/uploads/2020/05/Brainwork-TreatmentChoice-e1590771784850.jpg 1920 1280 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 29th May 2020 29th May 2020

While most patients with epilepsy respond to one or two drugs, it is estimated that 30% develop drug resistance.1 At EAN 2020, Sylvain Rheims (Department of Functional Neurology and Epileptology,…

Anne Carter, MA (Cantab)
0
0

25th September 2019

Why B-cell therapies, or why not?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-bcelltherapy.jpg 3848 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 25th September 2019 4th October 2019

The rational for B-cell therapy in multiple sclerosis (MS) was presented during ECTRIMS 2019, with David Baker (Blizard Institute, Queen Mary University of London, UK) posing the question of why…

Peter Stevenson, PhD
0
0

24th September 2019

Are stem cells in MS ready for prime time?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-stem-cells.jpg 2300 1535 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

Peter Stevenson, PhD
1
0

24th September 2019

Enough evidence for vitamin D in MS?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-vitamin-D.jpg 3450 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

The role of vitamin D in the treatment of multiple sclerosis (MS) took centre stage during the first day of ECTRIMS 2019 in Stockholm, Sweden. In a ‘Hot Topic’ session,…

Peter Stevenson, PhD
0
0